Erratum: Mechanism of MEK Inhibition Determines Efficacy in Mutant KRAS- Versus BRAF-driven Cancers

Nature - United Kingdom
doi 10.1038/nature12659
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Efficacy and Safety of BRAF Inhibition Alone Versus Combined BRAF and MEK Inhibition in Melanoma: A Meta-Analysis of Randomized Controlled Trials

Oncotarget
Oncology
2017English

Combined MEK and BCL-XL Inhibition Kills KRAS -Mutant Cells

Cancer Discovery
Oncology
2012English

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma

Cancers
Cancer ResearchOncology
2019English

Tissue of Origin Dictates Branched-Chain Amino Acid Metabolism in Mutant Kras-Driven Cancers

Science
MultidisciplinaryPhilosophy of ScienceHistory
2016English

SHP2 Inhibition Overcomes RTK-mediated Pathway Re-Activation in KRAS Mutant Tumors Treated With MEK Inhibitors

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2012English

Combination PI3K/MEK Inhibition Promotes Tumor Apoptosis and Regression in PIK3CA Wild-Type, KRAS Mutant Colorectal Cancer

Cancer Letters
Cancer ResearchOncology
2014English

Effective Use of PI3K and MEK Inhibitors to Treat Mutant Kras G12D and PIK3CA H1047R Murine Lung Cancers

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy